Work

Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.6507

Authors: Mendel Goldfinger, Anjali S. Advani, Irene Navarro Vicente, Jacqueline Suen Garcia, Geoffrey Lim Uy, Juan Miguel Bergua Burgues, Tapan M. Kadia, Xin Shelley Wang, Shukaib Arslan, Rory Shallis, Christine McMahon, Eric J. Feldman, Alan F. List, Marie Payton, Uma Borate

Institutions: Montefiore Medical Center, Cleveland Clinic, Hospital Universitari i Politècnic La Fe, Dana-Farber Cancer Institute, Washington University in St. Louis, Hospital San Pedro de Alcántara, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Moffitt Cancer Center, University of Colorado Anschutz, University of Colorado Denver, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162504482

Cites:

Cited by:

Related to: